27 Participants Needed

Epigenetic Regulation of Adipose Tissue Distribution in Obesity

(Eiffel 2 Trial)

Age: 18 - 65
Sex: Any
Trial Phase: Academic
Sponsor: Translational Research Institute for Metabolism and Diabetes, Florida
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

The purpose of this study is to collect data to help researchers better understand the different ways that women or men store fat (apple shape versus pear shape).

Will I have to stop taking my current medications?

The trial requires that you stop taking any medications known to influence glucose, fat, and/or energy metabolism within the last 3 months. If you are on blood thinners or antiplatelet medications, you may need to stop them for biopsy and testing procedures.

Is the treatment involving adipose tissue biopsies, DEXA/MRI, and MRS safe for humans?

The research articles provided do not contain specific safety data for the procedures mentioned, such as adipose tissue biopsies, DEXA/MRI, and MRS, in humans.12345

How does this treatment for obesity differ from other treatments?

This treatment is unique because it focuses on the epigenetic regulation of fat distribution, specifically through changes in DNA methylation and histone modifications, which are chemical changes that can turn genes on or off. Unlike traditional treatments that may focus on diet, exercise, or medication, this approach targets the underlying genetic and molecular mechanisms that influence how and where fat is stored in the body.14678

What data supports the effectiveness of this treatment for regulating adipose tissue distribution in obesity?

The research shows that MRI and MRS can reliably measure and analyze different types of fat tissue in the body, which is important for understanding how fat is distributed in obesity. This suggests that these imaging techniques are effective tools for studying and potentially managing obesity by providing detailed information about fat distribution.910111213

Who Is on the Research Team?

SR

Steven R Smith, MD

Principal Investigator

Study Principal Investigator

Are You a Good Fit for This Trial?

This trial is for men and women aged 18-45 with a BMI of 23-35, stable weight in the last three months, non-smokers, not pregnant or postpartum beyond nine months. Excluded are those with serious health conditions like uncontrolled hypertension, kidney/liver disease, recent heart attacks or cancer, untreated thyroid issues or certain mental illnesses.

Inclusion Criteria

HbA1C <6.0%
Weight stable (± 3 kg) during the 3 months prior to enrollment
Women must be > 9 months post-partum
See 2 more

Exclusion Criteria

Postmenopausal women
You have received an organ transplant in the past.
Creatinine > 2x upper limit of laboratory reference range, or known diagnosis of kidney disease
See 18 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants undergo biopsies and subsequent in vitro culture and analysis of adipose tissue

6 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • Adipose tissue biopsies
  • Dual-energy X-ray absorptiometry (DEXA)/ Magnetic resonance imaging (MRI) and Magnetic resonance spectroscopy (MRS)
  • FSIGTT/ RMR
Trial Overview Researchers are studying how adults store fat differently by using tests like FSIGTT/RMR to measure insulin sensitivity and metabolism; DEXA/MRI/MRS scans to visualize body composition; and adipose tissue biopsies to examine fat distribution at a cellular level.
How Is the Trial Designed?
3Treatment groups
Active Control
Group I: Group A- Women- Healthy 'pears'Active Control3 Interventions
This group will consist of healthy women with a BMI between 23 and 35 kg/m2 as a waist-to-hip ratio of 0.78 or less.
Group II: Group B- Women- Healthy 'apples'Active Control3 Interventions
The group will consist of healthy women with a BMI between 23 and 35 kg/m2 as a waist-to-hip ratio of 0.85 or more.
Group III: Group C- Men- Healthy 'apples'Active Control3 Interventions
The group will consist of men with a BMI between 23 and 35 kg/m2.

Find a Clinic Near You

Who Is Running the Clinical Trial?

Translational Research Institute for Metabolism and Diabetes, Florida

Lead Sponsor

Trials
41
Recruited
3,600+

AdventHealth Translational Research Institute

Lead Sponsor

Trials
51
Recruited
5,900+

Sanford-Burnham Medical Research Institute

Collaborator

Trials
9
Recruited
770+

Citations

Comparison of methods for assessing abdominal adipose tissue from magnetic resonance images. [2016]
Compensation of RF field and receiver coil induced inhomogeneity effects in abdominal MR images by a priori knowledge on the human adipose tissue distribution. [2012]
In vivo triglyceride composition of abdominal adipose tissue measured by 1 H MRS at 3T. [2018]
Feasibility and reproducibility of free fatty acid profiling in abdominal adipose tissue with 1H-magnetic resonance spectroscopy at 3 T: differences between lean and obese individuals. [2014]
Breast adipose tissue attenuation as a novel imaging biomarker for cardiometabolic risk. [2022]
Histone variants and their post-translational modifications in primary human fat cells. [2021]
Differential open chromatin profile and transcriptomic signature define depot-specific human subcutaneous preadipocytes: primary outcomes. [2019]
Nuclear and chromatin rearrangement associate to epigenome and gene expression changes in a model of in vitro adipogenesis and hypertrophy. [2023]
Human adipose tissue H3K4me3 histone mark in adipogenic, lipid metabolism and inflammatory genes is positively associated with BMI and HOMA-IR. [2020]
Genome Profiling of H3k4me3 Histone Modification in Human Adipose Tissue during Obesity and Insulin Resistance. [2021]
11.United Statespubmed.ncbi.nlm.nih.gov
Limits of Fat Quantification in the Presence of Iron Overload. [2022]
Dynamic DNA methylation landscape defines brown and white cell specificity during adipogenesis. [2018]
Human adipogenesis is associated with genome-wide DNA methylation and gene-expression changes. [2018]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security